Explore the vast range of titles available.

The absence of CAC in asymptomatic individuals is associated with a very low incidence of cardiovascular events. Of symptomatic patients, 1-2% with zero CAC score have non-calcified coronary artery atherosclerosis, and at least one third of cardiovascular events occur in individuals with zero CAC. South Asians (SA) have proportionally higher case fatality rates for CVD, relatively younger age of presentation, and accelerated rate of atherosclerosis when compared with other ethnic groups. All consecutive patients who underwent a CTCA to evaluate angina or angina-equivalent symptoms during the study duration were enrolled retrospectively. Patients with prior myocardial infarction, history of revascularization, and congenital heart disease were excluded. MACE was defined as the total of cardiac death, non-fatal myocardial infarction, and/or non-elective revascularization. A total of 534 patients were enrolled after final exclusion. The mean age was 53 years ± 11. Males constituted 68.4% of the study population. Dyslipidemia was the most common co-morbid condition identified (50%), followed by diabetes (18.4%) and hypertension (3.6%). At least 28.8% of patients with zero CAC scores had the presence of coronary artery disease (soft plaque) of any degree. Obstructive CAD (>50%) was present in 5.8% of patients. Follow-up was available for 61.4% of patients. On a mean follow-up of 96.6 months ± 49.8 (range 21-194 months), all-cause MACE was observed in 8.8% of patients. The most common MACE was angina (3.96%) and all-cause mortality (3%). The baseline characteristics and MACE did not differ in patients with and without obstructive CAD. The baseline characteristics did not differ significantly between patients with and without MACE. The incidence of soft plaque in this SA cohort is higher than that reported in international studies. However, in symptomatic SA, a CAC score of zero carries a good long-term prognosis, irrespective of the degree of CAD.

Background: This study is aimed at developing a prediction nomogram for subclinical coronary atherosclerosis in an Asian population with baseline zero score, and to compare its discriminatory ability with Framingham risk score (FRS) and atherosclerotic cardiovascular disease (ASCVD) models. Methods: Clinical characteristics, physical examination, and laboratory profiles of 830 subjects were retrospectively reviewed. Subclinical coronary atherosclerosis in term of Coronary artery calcification (CAC) progression was the primary endpoint. A nomogram was established based on a least absolute shrinkage and selection operator (LASSO)-derived logistic model. The discrimination and calibration ability of this nomogram was evaluated by Hosmer–Lemeshow test and calibration curves in the training and validation cohort. Results: Of the 830 subjects with baseline zero score with the average follow-up period of 4.55 ± 2.42 year in the study, these subjects were randomly placed into the training set or validation set at a ratio of 2.8:1. These study results showed in the 612 subjects with baseline zero score, 145 (23.69%) subjects developed CAC progression in the training cohort ( N = 612), while in the validation cohort ( N = 218), 51 (23.39%) subjects developed CAC progression. This LASSO-derived nomogram included the following 10 predictors: “sex,” age,” “hypertension,” “smoking habit,” “Gamma-Glutamyl Transferase (GGT),” “C-reactive protein (CRP),” “high-density lipoprotein cholesterol (HDL-C),” “cholesterol,” “waist circumference,” and “follow-up period.” Compared with the FRS and ASCVD models, this LASSO-derived nomogram had higher diagnostic performance and lower Akaike information criterion (AIC) and Bayesian information criterion (BIC) value. The discriminative ability, as determined by the area under receiver operating characteristic curve was 0.780 (95% confidence interval: 0.731–0.829) in the training cohort and 0.836 (95% confidence interval: 0.761–0.911) in the validation cohort. Moreover, satisfactory calibration was confirmed by Hosmer–Lemeshow test with P -values of 0.654 and 0.979 in the training cohort and validation cohort. Conclusions: This validated nomogram provided a useful predictive value for subclinical coronary atherosclerosis in subjects with baseline zero score, and could provide clinicians and patients with the primary preventive strategies timely in individual-based preventive cardiology.

Background: Olopatadine hydrochloride ophthalmic solution 0.2% (PATADAY™; Alcon, Fort Worth, TX) (olopatadine 0.2%) is a formulation of a multi-action agent that has been approved for the treatment of ocular itching associated with allergic conjunctivitis when used once daily. Objective: To evaluate olopatadine 0.2% versus its vehicle in the complete prevention of ocular itching in adult patients with allergic conjunctivitis. Methods: This paper presents a post-hoc analysis of subgroup results from a single-center, double-masked, randomized, contralateral eye, conjunctival allergen challenge study. The post-hoc efficacy analysis, conducted with data from patients who instilled olopatadine 0.2% in a single eye and vehicle in the contralateral eye, compared the ability of each study formulation to completely prevent ocular itching at three assessment time points post-instillation. Safety was not reevaluated in the post-hoc analysis. Results: Overall, 40 patients received contralateral instillations of study drug and were included in the post-hoc analysis. At all three post-instillation time points, significantly greater proportions of patients reported itching scores of 0 in the olopatadine 0.2%-treated eye than in the vehicle-treated eye (63%–65% versus 3%–10%, respectively; P < 0.05 for each comparison). Within the previously reported results for the full study, no clinically relevant or statistically significant changes from baseline were observed for patients in regard to visual acuity, ocular signs, or fundus parameters. Conclusion: Olopatadine 0.2% is safe, well tolerated, and superior to vehicle in completely preventing ocular itching that results from allergen exposure following drug instillation in patients with allergic conjunctivitis.